|
1
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oliveira-Neto HH, Gleber-Netto FO, de
Sousa SF, França CM, Aguiar MC, Silva TA and Batista AC: A
comparative study of microvessel density in squamous cell carcinoma
of the oral cavity and lip. Oral Surg Oral Med Oral Pathol Oral
Radiol. 113:391–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang X, Zhou H, Liu X, He Y, Tang Y, Zhu
G, Zheng M and Yang J: Effect of local hyperthermia on
lymphangiogenic factors VEGF-C and -D in a nude mouse xenograft
model of tongue squamous cell carcinoma. Oral Oncol. 46:111–115.
2010. View Article : Google Scholar
|
|
7
|
Strome SE, Dong H, Tamura H, Voss SG,
Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al:
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous
cell carcinoma. Cancer Res. 63:6501–6505. 2003.PubMed/NCBI
|
|
8
|
Lyford-Pike S, Peng S, Young GD, Taube JM,
Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, et
al: Evidence for a role of the PD-1:PD-L1 pathway in immune
resistance of HPV-associated head and neck squamous cell carcinoma.
Cancer Res. 73:1733–1741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zandberg DP and Strome SE: The role of the
PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck.
Oral Oncol. 50:627–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsushima F, Tanaka K, Otsuki N, Youngnak
P, Iwai H, Omura K and Azuma M: Predominant expression of B7-H1 and
its immunoregulatory roles in oral squamous cell carcinoma. Oral
Oncol. 42:268–274. 2006. View Article : Google Scholar
|
|
14
|
Iwai Y, Terawaki S and Honjo T: PD-1
blockade inhibits hematogenous spread of poorly immunogenic tumor
cells by enhanced recruitment of effector T cells. Int Immunol.
17:133–144. 2005. View Article : Google Scholar
|
|
15
|
Hirano F, Kaneko K, Tamura H, Dong H, Wang
S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al: Blockade of
B7-H1 and PD-1 by monoclonal antibodies potentiates cancer
therapeutic immunity. Cancer Res. 65:1089–1096. 2005.PubMed/NCBI
|
|
16
|
Ibrahim R, Stewart R and Shalabi A: PD-L1
blockade for cancer treatment: MEDI4736. Semin Oncol. 42:474–483.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen L, Gibbons DL, Goswami S, Cortez MA,
Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al: Metastasis
is regulated via microRNA-200/ZEB1 axis control of tumour cell
PD-L1 expression and intratumoral immunosuppression. Nat Commun.
5:52412014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prudkin L, Liu DD, Ozburn NC, Sun M,
Behrens C, Tang X, Brown KC, Bekele BN, Moran C and Wistuba II:
Epithelial-to-mesenchymal transition in the development and
progression of adenocarcinoma and squamous cell carcinoma of the
lung. Mod Pathol. 22:668–678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zavadil J, Haley J, Kalluri R, Muthuswamy
SK and Thompson E: Epithelial-mesenchymal transition. Cancer Res.
68:9574–9577. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uramoto H, Iwata T, Onitsuka T, Shimokawa
H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in
EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res.
30:2513–2517. 2010.PubMed/NCBI
|
|
22
|
Chung JH, Rho JK, Xu X, Lee JS, Yoon HI,
Lee CT, Choi YJ, Kim HR, Kim CH and Lee JC: Clinical and molecular
evidences of epithelial to mesenchymal transition in acquired
resistance to EGFR-TKIs. Lung Cancer. 73:176–182. 2011. View Article : Google Scholar
|
|
23
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kimura I, Kitahara H, Ooi K, Kato K,
Noguchi N, Yoshizawa K, Nakamura H and Kawashiri S: Loss of
epidermal growth factor receptor expression in oral squamous cell
carcinoma is associated with invasiveness and
epithelial-mesenchymal transition. Oncol Lett. 11:201–207.
2016.PubMed/NCBI
|
|
25
|
Yokoi T, Hirata S, Nishimura F, Miyakawa
A, Odajima T, Kohama G and Mochizuki Y: Some properties of a newly
established human cell line derived from an oral squamous
carcinoma. Tumor Res. 25:93–103. 1990.
|
|
26
|
Yokoi T, Homma H and Odajima T:
Establishment and characterization of OSC-19 cell line in serum and
protein free culture. Tumor Res. 24:1–17. 1988.
|
|
27
|
Hayashi E, Rikimaru K and Nagayama M:
Simultaneous production of G- and M-CSF by an oral cancer cell line
and the synergistic effects on associated leucocytosis. Eur J
Cancer B Oral Oncol. 31B:323–327. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arrighi JF, Hauser C, Chapuis B, Zubler RH
and Kindler V: Long-term culture of human CD34(+) progenitors with
FLT3-ligand, thrombopoietin, and stem cell factor induces extensive
amplification of a CD34(−)CD14(−) and a CD34(−)CD14(+) dendritic
cell precursor. Blood. 93:2244–2252. 1999.PubMed/NCBI
|
|
29
|
Yang D, Chen Q, Le Y, Wang JM and
Oppenheim JJ: Differential regulation of formyl peptide
receptor-like 1 expression during the differentiation of monocytes
to dendritic cells and macrophages. J Immunol. 166:4092–4098. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Evans RA, Tian YC, Steadman R and Phillips
AO: TGF-beta1-mediated fibroblast-myofibroblast terminal
differentiation - the role of Smad proteins. Exp Cell Res.
282:90–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Adam L, Zhong M, Choi W, Qi W, Nicoloso M,
Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al:
miR-200 expression regulates epithelial-to-mesenchymal transition
in bladder cancer cells and reverses resistance to epidermal growth
factor receptor therapy. Clin Cancer Res. 15:5060–5072. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thompson L: World Health Organization
classification of tumours: Pathology and genetics of head and neck
tumours. Ear Nose Throat J. 85:742006.PubMed/NCBI
|
|
33
|
Yamamoto E, Kohama G, Sunakawa H, Iwai M
and Hiratsuka H: Mode of invasion, bleomycin sensitivity, and
clinical course in squamous cell carcinoma of the oral cavity.
Cancer. 51:2175–2180. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
35
|
Kawashiri S, Kumagai S, Kojima K, Harada H
and Yamamoto E: Development of a new invasion and metastasis model
of human oral squamous cell carcinomas. Eur J Cancer B Oral Oncol.
31B:216–221. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moriyama M: Development of diffuse
invasive (grade 4D) human oral squamous cell carcinoma model in
severe combined immunodeficiency mice: Microangioarchitectural
analysis and immunohistochemical study. Oral Oncol. 35:395–400.
1999. View Article : Google Scholar
|
|
37
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wintterle S, Schreiner B, Mitsdoerffer M,
Schneider D, Chen L, Meyermann R, Weller M and Wiendl H: Expression
of the B7-related molecule B7-H1 by glioma cells: A potential
mechanism of immune paralysis. Cancer Res. 63:7462–7467.
2003.PubMed/NCBI
|
|
39
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ohigashi Y, Sho M, Yamada Y, Tsurui Y,
Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al:
Clinical significance of programmed death-1 ligand-1 and programmed
death-1 ligand-2 expression in human esophageal cancer. Clin Cancer
Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Thompson RH and Kwon ED: Significance of
B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer.
5:206–211. 2006. View Article : Google Scholar
|
|
42
|
Hamanishi J, Mandai M, Iwasaki M, Okazaki
T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N,
et al: Programmed cell death 1 ligand 1 and tumor-infiltrating
CD8+ T lymphocytes are prognostic factors of human
ovarian cancer. Proc Natl Acad Sci USA. 104:3360–3365. 2007.
View Article : Google Scholar
|
|
43
|
Nomi T, Sho M, Akahori T, Hamada K, Kubo
A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, et al:
Clinical significance and therapeutic potential of the programmed
death-1 ligand/programmed death-1 pathway in human pancreatic
cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ghebeh H, Tulbah A, Mohammed S, Elkum N,
Bin Amer SM, Al-Tweigeri T and Dermime S: Expression of B7-H1 in
breast cancer patients is strongly associated with high
proliferative Ki-67-expressing tumor cells. Int J Cancer.
121:751–758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yao Y, Tao R, Wang X, Wang Y, Mao Y and
Zhou LF: B7-H1 is correlated with malignancy-grade gliomas but is
not expressed exclusively on tumor stem-like cells. Neuro-oncol.
11:757–766. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Okazaki T, Chikuma S, Iwai Y, Fagarasan S
and Honjo T: A rheostat for immune responses: The unique properties
of PD-1 and their advantages for clinical application. Nat Immunol.
14:1212–1218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nazareth MR, Broderick L, Simpson-Abelson
MR, Kelleher RJ Jr, Yokota SJ and Bankert RB: Characterization of
human lung tumor-associated fibroblasts and their ability to
modulate the activation of tumor-associated T cells. J Immunol.
178:5552–5562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: KEYNOTE-001 Investigators: Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL,
et al: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra372012. View Article : Google Scholar : PubMed/NCBI
|
